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Background: Despite recent advances in the treatment for advanced prostate cancer, outcomes remain poor.
This lack of efficacy has prompted the development of alternative treatment strategies. In the present study we
investigate the effects of the multikinase inhibitor sorafenib in a genetically engineered mouse model of prostate
cancer and explore the rational combination with the mTOR inhibitor everolimus.
Methods: Conditional prostate specific PTEN-deficient knockout mice were utilized to determine the
pharmacodynamic and chemopreventive effects of sorafenib. This mouse model was also used to examine the
therapeutic efficacy of sorafenib alone or in combination with everolimus. Preclinical efficacy was assessed by
comparing the reduction of tumor burden, proliferation, angiogenesis and the induction of apoptosis. Molecular
responses were assessed by immunohistochemical, TUNEL and western blot assays.
Results: Pharmacodynamic analysis revealed that a single dose of sorafenib decreased activation of the PI3K/AKT/
mTOR signaling axis at doses of 30–60 mg/kg, but activated JAK/STAT3 signaling. Levels of cleaved casapase-3
increased in a dose dependent manner. Chemoprevention studies showed that chronic sorafenib administration
was capable of inhibiting tumor progression through the reduction of cancer cell proliferation, angiogenesis and
the induction of apoptosis. In intervention models of established castration-naïve and castration-resistant prostate
cancer, treatment with sorafenib provided modest but statistically insignificant reduction in tumor burden. However,
sorafenib significantly inhibited cancer cell proliferation and MVD but had minimal effects on the induction of
apoptosis. Interestingly, the administration of sorafenib increased the expression levels of the androgen receptor,
p-GSK3β and p-ERK1/2 in castration-resistant prostate cancers. In both intervention models, combination therapy
demonstrated a clear tendency of enhanced antitumor effects over monotherapy. Notably, the treatment
combination of sorafenib and everolimus overcame therapeutic escape from single agent therapy in
castration-resistant prostate cancers.
Conclusions: In summary, we provide insights into the molecular responses of sorafenib therapy in a
clinically relevant model of prostate cancer and present preclinical evidence for the development of targeted
treatment strategies based on the use of multikinase inhibitors in combination with mTOR inhibitors for the
treatment of advanced prostate cancer.
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Strides have been made for the treatment of localized
prostate cancer, including surgery and radiotherapy,
however, androgen deprivation therapy (ADT) remains
the standard treatment of advanced prostate cancer.
Even though tumors initially respond to ADT, most
patients invariably develop lethal castration-resistant
prostate cancer (CRPC) within only a few years after the
initiation of ADT [1-3]. Several new agents such as
docetaxel, cabazitaxel, abiraterone acetate, enzalutamide
and sipuleucel-T have shown some clinical improve-
ments for CRPC patients, however, responses are modest
and the median increase in survival remains poor [4-8].
Thus, novel treatment strategies that could prevent
disease progression in CRPC are needed. Recently, a
number of small molecules targeting kinases have been
developed and have been or are undergoing clinical
evaluation. Kinases have the potential to be effective
targets for anticancer therapy since these modulate a
number of signal transduction cascades. Moreover, many
of these kinases play roles in modulating transformed
malignant cells as well as non-malignant cells in the
tumor microenvironment.
Sorafenib is an oral multi-targeted kinase inhibitor
that has demonstrated the ability to suppress Raf kinases
as well as a number of receptor tyrosine kinases (RTK)
implicated in tumor progression and angiogenesis [9].
Sorafenib has been shown to act directly on human
prostate cancer cells decreasing cellular proliferation and
inducing apoptosis through the downregulation of AKT
and androgen receptor pathways [10]. Moreover sorafe-
nib has been shown to inhibit the activity of full length
AR and AR lacking the AR-ligand binding domain in
CRPC cells [11]. However, neither sorafenib nor suniti-
nib, another multi-targeted RTK inhibitor, have lived up
to their promise as single agent therapy having shown
only modest clinical benefits in human CRPC [12-17].
This lack of efficacy suggests that other pathways are
involved in the survival and growth of tumors. In
addition, treatment with sorafenib can lead to the activa-
tion of c-Met and mTOR in some cell types [18].
The PI3K/AKT/mTOR pathway plays a crucial role in
the development of prostate cancer and transformation
to CRPC. In metastatic prostate cancer, alterations of
the PI3K/AKT/mTOR pathway have been reported in
100% of cases [19]. These alterations occur as a result of
AKT activation due to loss of function of the tumor
suppressor phosphatase and tensin homolog (PTEN)
[20]. As a result, a great deal of interest has been focused
in developing therapeutic agents targeting the PI3K/
AKT/mTOR signaling axis. Due to their promising
results in preclinical models, several rapalogs, including
everolimus, have been tested in the clinical setting but
have met disappointing outcomes [17,21-23]. Recentstudies have shown that in certain cancer cell types,
combining sorafenib with mTOR inhibitors can over-
come therapeutic escape [18,24-29].
In this study, we utilize a genetically engineered mouse
model of PTEN-deficient prostate cancer to characterize
the effects of sorafenib on castration-naïve and
castration-resistant prostate tumors. We also utilize this
mouse model to explore the efficacy of combination
therapy with sorafenib and the mTOR inhibitor
everolimus.Material and methods
Reagents and antibodies
Sorafenib tysolate and everolimus were purchased form
L.C. Laboratories (Woburn, MA). For all in vivo stud-
ies, sorafenib and everolimus were prepared as previ-
ously described [9,30]. Antibodies for western blot and
immunohistochemical analysis were purchased as
follows: β-catenin (#8480), Bcl-2 (#2870), BIM (#2933),
cleaved caspase-3 (#9661), ERK (#9102), GAPDH
(#2118), mTOR (#2983), p-β-catenin (#9561), p-ERK
(#4370), p-mTOR (#2971), p-S6 (#2211), p-STAT3-
pY705 (#9145), p-STAT3-pY727 (#9134), S6 (#2217)
and STAT3 (#4904) antibodies from Cell Signaling
Technology (Danvers, MA); AR (#RB-9030), PCNA
(#RB-9055) and Ki67 (#RB-9043) antibodies from
Thermo Scientific (Waltham, MA); cyclin B1 (sc-752), cyc-
lin D1 (sc-753) antibodies from Santa Cruz Biotechnology
(Dallas, TX); CD31 (#550300) from BD Biosciences (San
Jose, CA).Animals
Homozygous PTEN-conditional knockout (PSACre/
PTENFlox/Flox) mice were used for this study. The
characterization of this animal model has been described
previously [30]. Briefly, we used the PSA-Cre promoter
to mediate Cre-lox recombination of exons 4 and 5
(exon 5 encodes the crucial phosphatase core motif ).
This results in the prostate-specific inactivation of PTEN
in the dorsolateral and ventral lobes of the prostate. In
homozygous mutants, PSA-Cre driven inactivation of
PTEN leads to the development of mouse low grade
prostatic intraepithelial neoplasia (lgPIN) at 8 weeks of
age which progresses to mouse high grade PIN (hgPIN,
a precursor to invasive adenocarcinoma) by 15 weeks of
age. To induce CRPC, homozygous PTEN-conditional
knockout mice were anesthetized and surgically
castrated at 10–12 weeks of age. All experiments were
approved by the Institutional Review Committee at
Kinki University Faculty of Medicine. Mice were main-
tained in accordance with institutional guidelines and
procedures were carried out in compliance with the
standards for use of laboratory animals.
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Pharmacodynamics effects of sorafenib were performed
on 20-week-old PTEN-mutant mice harboring castration-
naïve prostate cancer (CNPC). Sorafenib was administered
as a single dose and mice were sacrificed after 24 h.
Tumor samples were dissected and processed for western
blot analysis.
Drug chemoprevention studies
Chemoprevention studies were performed on six-week-
old PTEN-mutant mice. Sorafenib was administered
orally by gavage (30 mg/kg, 3X/week) beginning at six
weeks of age and was continued until the animals were
15 weeks or 20 weeks of age, at which time the experi-
ment was terminated. The animals were sacrificed and
the genitourinary tracts (GUT) were collected en bloc,
weighed, imaged, and processed for histopathological,
immunohistochemical (IHC), and western blot analysis.
Drug intervention studies
Drug efficacy was determined by performing drug inter-
vention studies on 16-week-old PTEN-mutant mice
harboring CNPC or CRPC. To induce CRPC, mice were
surgically castrated at 10 weeks of age as previously
described [30]. Mice were randomized and assigned to
treatment groups consisting of control (equal volume of
vehicle, 5X/week), sorafenib (gavage, 30 mg/kg, 5X/week),
everolimus (oral gavage, 10 mg/kg, 3X/week) or combin-
ation sorafenib (gavage, 30 mg/kg, 5X/week) and everoli-
mus (gavage, 10 mg/kg, 3X/week) for 4 weeks. Mice were
sacrificed and the GUTs were removed en bloc, weighed,
imaged and processed for histopathological, IHC, TUNEL
and western blot analysis.
Tumor burden and efficacy determination
Tumor burden was determined by fresh GUT weight or
prostate surface area. The surface area of prostate,
containing tumor tissue was determined using gross im-
ages of fresh GUTs as previously described [30]. Digital
images were captured using a Nikon Coolpix 995 digital
camera attached to an Olympus SX61 stereomicroscope.
The images were spatially calibrated and area measure-
ments were obtained using ImageJ image analysis
software [31]. Drug antitumor efficacy was determined
by differences in GUTs weight or prostate surface area.
Histology and immunohistochemical analysis
GUTs were fixed overnight in 10% neutral buffered
formalin. Tissues were processed, embedded in paraffin,
sectioned and stained with hematoxylin and eosin using
standard methods. IHC analysis was performed accord-
ing to the standard protocols described previously [32].
Assessment of staining was performed visually or usingImageJ analysis software with the Landini color decon-
volution plugin V1.5 [33].
Distribution analysis
Distribution analysis of tumor stroma and epithelial cells
compartments was performed on photomicrographs of
H&E stained cross sections of the GUT taken at 40X
magnification and digitally stitched with Photoshop CS5
Extended (Adobe Systems Inc. San Jose CA). Images
were spatially calibrated and digital image masks corre-
sponding to dorsolateral and ventral prostate lobes were
painted on. In addition, separate masks corresponding to
stroma, normal acini, lgPIN and hgPIN within the
dorsolateral and ventral prostates were also generated
(Additional file 1: Figure S1). Area measurements corre-
sponding to each individual mask were recorded by the
software and exported to a spreadsheet for further statis-
tical analysis.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick endlabeling assay
Terminal deoxynucleotidyl transferase-mediated dUTP
nick endlabeling (TUNEL) assays were determined using
the In Situ Cell Death Detection Kit (Roche Diagnostics
Corporation, Indianapolis, IN) according to methods
previously described [32].
Western blot analysis
Protein extraction and immunoblotting were performed
as previously described [32]. Semi-quantitative densito-
metric analyses were assessed using ImageJ analysis
software. For all densitometric analyses, protein levels
were normalized to GAPDH or total protein.
Statistical analysis
Data were reported as mean values ± standard error and
were statistically analyzed using the Student’s t-test for
paired analysis and one-way ANOVA for multiple
comparisons. P < 0.05 was considered statistically signifi-
cant. Statistical analysis was carried out using Sigmaplot
v.13.0 (Systat Software, Inc. San Jose, CA).
Results
Pharmacodynamic effects of sorafenib
In order to establish the preliminary activity of sorafenib
in our mouse model and to determine a suitable dose
for the intervention studies, we assessed the pharmaco-
dynamic effects of a single dose of sorafenib on the acti-
vation of downstream molecules of MAPK, PI3K/AKT/
mTOR and JAK/STAT signal transduction pathways,
and markers of cellular proliferation and apoptosis. Our
findings revealed that for the most part activation of
Erk1/2 remained unaffected up to doses of 45 mg/kg,
however, levels of phosphorylation increased at 60 and
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stream target molecule of the PI3K/AKT/mTOR signal-
ing axis, decreased at doses of 30–60 mg/kg, butFigure 1 Pharmacodynamic effects of sorafenib administration. Sorafenib w
PTEN-deficient mice at 20 weeks of age. Prostate tumor lysates were prepa
of phosphorylated and total proteins of ERK, S6 and STAT3, and glyceralde
of p-ERK/ERK, p-S6/S6 and p-STAT3-pY705/STAT3. (C) Densitometric analysi
to GAPDH. Plots are expressed as the mean ± s.e.increased at the maximum dose of 75 mg/kg (Figure 1
A-B). A dose-dependent activation of STAT3 at tyr705
was also observed (Figure 1A-B). For the most part,as administered at the indicated doses for 24 h to castration-naïve
red and protein levels were analyzed by western blot. (A) Protein levels
hyde 3-phosphate dehydrogenase (GAPDH). (B) Densitometric analysis
s of Cyclin D1, Cyclin B1, BIM, Bcl-2 and Cleaved Caspase-3 normalized
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single administration of sorafenib, however, levels of cycling
B1 expression were elevated at doses of 45 and 60 mg/kg
(Figure 1A,C). Interestingly, there was a dose-dependent ef-
fect on the expression levels of pro-apoptotic proteins
(BIM and cleaved caspase-3) and decrease of anti-apoptotic
Bcl-2 (Figure 1A,C). Based on these findings, we decided to
test the efficacy of chronic sorafenib administration at a
dose of 30 mg/kg.Sorafenib suppresses PTEN-deficient tumor progression
To characterize the antitumor effects of sorafenib
in vivo, we first sought to determine the chemopreven-
tive effects on PTEN-deficient prostate cancer develop-
ment. In our conditional PTEN-knockout mouse model,
mice are born cancer-free and develop PIN at eight
weeks of age. By 10 weeks of age, half of the mice
develop low grade tumors and by 15 weeks 100% of
mice develop cancers [30]. From 15 to 20 weeks of age,
tumors grow quickly and thus provide an excellent
window to assess changes in tumor growth and progres-
sion. Therefore, we administered sorafenib orally at a
dose of 30 mg/kg 3X/week to cancer-free six-week-old
PTEN-mutant mice and compared differences in tumor
development at 15 and 20 weeks of age. The effects on
tumor burden are shown in Figure 2. Compared to
vehicle controls, tumor burden based on GUT weight
was significantly reduced after treatment with sorafenib
in the 20-week-old group (Figure 2A-B). Histologically,
tumors from mice treated with sorafenib demonstrated
morphological changes in tumor architecture that
consisted of decreased reactive stroma and distension of
prostatic acini congested with coagulated secretory
material (Figure 2C).
To further assess the effects on tumor progression
after treatment with sorafenib, we performed histological
analysis of the tissue distribution patterns of stromal and
glandular tissue within the prostate tumors. This analysis
measures differences in tumor development and pro-
gression. Control mice showed an increase in the pros-
tate area, consisting of the dorsolateral and ventral
prostates between 15 and 20 weeks (Figure 2C). In
addition, increases in the stromal and epithelial com-
partments were also observed. Significant differences
between the absolute area measurements of normal and
cancerous (hgPIN) glands were observed, but these did
not reflect changes in the relative proportions of trans-
formed glands (Figure 2D-E). Notably, mice treated with
sorafenib exhibited decreases in the absolute area
measurements of the whole prostate, epithelial and
stromal compartments, and normal and cancerous
glands (Figure 2D). Moreover, marked differences
were observed in the relative proportions of the distributionof PIN and cancerous glands in the prostates of control and
sorafenib-treated mice at 20 weeks.
We also determined the antiangiogenic effects of
treatment with sorafenib in prostate tumors. CD31 was
used to analyze microvessel densities (MVD) and
microvessel area (MVA). Mice receiving sorafenib for a
total of 14 weeks had lower MVD and MVA compared
to vehicle-treated controls (Figure 3A-C and Additional
file 2: Figure S2). Mice receiving sorafenib also demon-
strated significantly lower tumor proliferation (Ki67)
rates and induction of apoptosis (TUNEL, Figure 3A,D-E).
Altogether, these data show that although sorafenib did not
affect the onset of prostate cancer, however, it repressed
disease progression through the inhibition of angiogenesis
and proliferation, and the induction of apoptosis.
Therapeutic intervention with sorafenib reduces PCa
growth and reverses resistance to everolimus in CRPC
We next determined the effects of sorafenib on estab-
lished prostate tumors. Ina addition, we hypothesized
that by targeting both the epithelial cancer cells and
cells of the tumor microenvironment could potentiate
the antitumor effects of sorafenib. Therefore, we evalu-
ated the antitumor effects of treatment for four weeks
with sorafenib alone or in combination with the mTOR
inhibitor everolimus in 16-week-old mice with PTEN-
deficient CNPC and CRPC. Treatment effects of the
drug interventions, determined by differences in tumor
burden measured by tumor area, are shown in Figure 4.
An 18% reduction of tumor burden was observed for
mice receiving sorafenib monotherapy in both CNPC
and CRPC intervention models, however, it was statisti-
cally insignificant (Figure 4A-C). In concordance with
our previous report [30], monotherapy with everolimus
elicited an antitumor effect only in mice with CNPC
but not CRPC (Figure 4A-C). Although statistically
insignificant (do not test result), the treatment combin-
ation of sorafenib and everolimus demonstrated a
tendency of augmented tumor burden reductions over
monotherapy (18.5% and 11.9% reduction of tumor
burden in sorafenib and everolimus treatment groups,
respectively) in the CNPC cohort (Figure 4A-B). In the
CRPC treatment group, combination therapy overcame
therapeutic escape of mTOR monotherapy and provided a
modest but statistically insignificant improvement over
sorafenib monotherapy (Figure 4A and C).
IHC analysis of Ki67 expression revealed significant
suppression of tumor proliferation rates in all mice
receiving drug treatments in the CNPC intervention
model. Tumor cell proliferation was more strongly
inhibited in mice receiving sorafenib compared to
everolimus; still, the combination of the two drugs did
not augment the antiproliferative effect (Figure 4D). In
the CRPC intervention model, only modest reductions
Figure 2 Chemopreventive effects of sorafenib on mouse PTEN-deficient prostate hgPIN. Six-week-old PTEN-deficient mice were treated with
sorafenib (30 mg/kg 3X/week for nine or 14 weeks, n = 8 mice/group). (A) Representative GUTs from mice after indicated treatment. Prostate
tumors are highlighted in yellow. Scale is represented in mm. (B) Plots of tumor burden assessed by GUT weight and expressed as the mean ± s.e.,
*P < 0.05. (C) Representative H&E stained tissue sections from mice after indicated treatment. Prostate tumors are delineated by the red dotted line.
Scale bars represent 5 mm. (D) High magnification images of representative H&E stained tissue sections from mice after indicated treatment.
Morphological differences in dysplastic glands (*) and stroma (s) are shown. Scale bars represent 100 μm. (E) Plots of absolute tumor tissue
distribution analysis expressed as the mean ± s.e., * P < 0.05, **P < 0.01. (F) Plots of relative tumor tissue distribution analysis expressed as the
percent of tumor involvement.
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ceiving monotherapy with either sorafenib or everoli-
mus, however, combined therapy synergized to enhance
the inhibition of tumor cell proliferation (Figure 4D).
The apoptotic rate of CNPC tumors treated with com-
bination therapy was significantly greater than that
after monotherapy with either sorafenib or everolimus
(Figure 4E). In the CRPC model, combination therapy
did not result in improved apoptotic rates compared to
monotherapy (Figure 4E).We next evaluated the antiangiogenic responses in
the tumor stroma after treatment with sorafenib and
compared the effects to combination therapy with
everolimus. Antiangiogenic responses based on MVD
are shown in Figure 5. Treatment with everolimus
alone did not affect MVD in either the CNPC or CRPC
intervention models. On the other hand, treatment
with sorafenib resulted in significant decreases in MVD
in both CNPC and CRPC models, however, a higher
reduction was observed in the CRPC model (Figure 5A-B).
Figure 3 Sorafenib chemoprevention suppresses tumor angiogenesis, proliferation and induces apoptosis. Prostate tumors from 20-week-old control
and sorafenib-treated conditional PTEN-knockout mice well collected and analyzed to measure MVD and proliferation by IHC for the expression of
CD31 and PCNA, respectively, apoptosis by the TUNEL assay. (A) Representative CD31 and PCNA immunostained and TUNEL sections of prostate
cancer. Positive cells are stained brown. Scale bars represent 100 μm. Plots of MVD (B) and microvessel area (C) expressed as the mean ± s.e.
Plots of cancer cell proliferation rates based on PCNA expression (D) and apoptotic rates based on TUNEL positive cells (E). Values are expressed
as the mean ± s.e.
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Figure 4 Therapeutic effects of combination therapy with sorafenib and everolimus in PTEN-deficient prostate cancer. PTEN-deficient mice with
CNPC and CRPC were treated with sorafenib, everolimus or sorafenib plus everolimus for 4 weeks as described in the materials and methods
(n = 8 mice/group). (A) Representative images of GUTs from mice after indicated treatment. Prostate tumors are highlighted in yellow. Scale is
represented in mm. Plots of tumor burden assessed by tumor surface area for CPNC (B) and CRPC (C) intervention models. Plots of cellular
proliferation rates relative to control mice assessed by the number of Ki67-positive/Ki67-negative cancer cells (D) and the cellular apoptotic
rates relative to control mice assessed by the number of TUNEL-positive cells bodies/total negative cancer cells (E). All plot values represent the
percent of control expressed as the mean ± s.e., *P < 0.05, **P < 0.001.
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enhance the antiangiogenic effects of sorafenib.
Molecular characterization of major signal pathways in
response to combination therapy with sorafenib and
everolimus
To further characterize the mechanisms by which
sorafenib and everolimus function to inhibit tumor
growth in PTEN-deficient prostate cancer, we investi-
gated the activation of signal transduction pathwaysassociated prostate cancer progression. The expression
levels of AR as well as proteins involved in PI3K/AKT,
MAPK, and STAT3 signaling pathways were assessed in
prostate tissues from mice both CNPC and CRPC inter-
vention experiments (Figure 6). Average levels of AR
decreased notably in CNPC mice receiving everolimus,
however, mice receiving sorafenib alone or in combin-
ation with everolimus experienced marginal reductions
(Figure 6A-B). In the CRPC intervention model, mice
receiving sorafenib exhibited >2-fold increase in AR
Figure 5 Anti-angiogenic effects of combination therapy with sorafenib and everolimus in PTEN-deficient prostate cancer. Assays of MVD
assessed in prostate tumors from mice with CNPC and CRPC after drug interventions. (A) Representative images showing CD31 immunostaining
of prostate tumors after the indicated treatment. Scale bars represent 100 μm. (B) Quantitative analysis of MVD according to the presence of
CD31-positive microvessels. Values are expressed as the mean ± s.e., *P < 0.05.
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Monotherapy with everolimus had a minimal suppres-
sive effect on AR expression, and when administered in
combination with sorafenib, partially prevented the
increase in expression (Figure 6A,C). However, neither
treatment decreased the nuclear translocation of AR
(Additional file 3: Figure S3)
As expected, levels of AKT phosphorylation increased
in response to treatment with everolimus. However,
responses to sorafenib varied between individual animals
in both CNPC and CRPC intervention models. Interest-
ingly, combination therapy reduced p-AKT levels in the
CNPC treatment group, but levels rose in the CRPC
group. Notably, phosphorylation of GSK3β in CRPC
decreased mice despite elevated levels of phosphorylated
AKT suggesting that the combination of so sorafenib
and everolimus might cooperate to suppress GSK3 β
activity in CRPC. For the most part, other AKT
substrates showed similar tendencies of phosphorylation
as p-AKT. Treatment with sorafenib alone reduced thelevels of Erk1/2 phosphorylation and the effect was fur-
ther enhanced by the co-administration of everolimus in
CNPC (Figure 6A,B). In sharp contrast, mice with CRPC
showed a ~2-fold increase in the levels of Erk1/2
phosphorylation after treatment with sorafenib. Relative
levels of p-Erk1/2 did not vary with the administration of
everolimus. In fact, adding everolimus to sorafenib con-
tributed to reducing the upsurge of Erk1/2 phosphoryl-
ation (Figure 6A,C).
We examined the activation of the JAK/STAT3 path-
way by analyzing the transcription activation of STAT3
though its phosphorylation at tyrosine 705 (pY705) and
serine 727 (pY727) residues. In the CNPC intervention
model, levels of constitutively active STAT3-pY705
decreased in response to treatment with sorafenib or
everolimus, and combination therapy with both agents
markedly reduced transcriptional activity. Overall, the
relative levels of STAT3-pY727 phosphorylation were
unchanged with monotherapy but were notably reduced
with combination therapy (Figure 6A,B). In the CRPC
Figure 6 Molecular profiles of PTEN-deficient prostate cancer after
combination therapy with sorafenib and everolimus. (A) Expression
of AR, GAPDH, and phosphorylated and total proteins of AKT, GSK3β,
β-catenin, mTOR, S6, 4E-BP1, EIF-4B, ERK1/2 and STAT3 in prostate
tumor lysates from mice with CNPC and CRPC after the indicated
treatments. Densitometric analysis of (A) in CNPC (B) and CRPC (C)
intervention models. GAPDH was used as a loading control. Relative
protein expression levels were normalized to GAPDH for AR or
corresponding total protein for phosphorylated proteins. Plots are
expressed as the mean ± s.e. relative to control.
Yamamoto et al. Journal of Translational Medicine  (2015) 13:150 Page 10 of 12intervention model, treatment with sorafenib did not
affect phosphorylation of STAT3-pY705, however, treat-
ment with everolimus alone or in combination with
sorafenib tended to increase the expression levels of
STAT3-pY705 (Figure 6A,C). Levels of STAT3-pY727
increased in response to treatment with sorafenib.
However, this finding was not unexpected since
phosphorylation of the serine residue is regulated by the
MAPK pathway and the expression pattern of p-STAT3-
pY727 paralleled that of p-Erk1/2 (Figure 6A,C).
Discussion
Prostate tumors are complex structures made up of
normal and aberrant epithelial cells that are surrounded
by a stromal component composed of fibroblast, endo-
thelial and inflammatory cell populations. This heteroge-
neous cell mixture provides the structural and metabolic
support that allows cancer cells to survive and progress
into aggressive phenotypes. The tumor’s stromal vascu-
lar network plays a particularly important role since it
co-evolves along neoplastic and structural cells. This
vascular network, composed of neoangiogenic micro-
vessel, functions in the transport of oxygen, essential
nutrients and growth factors to all cell populations
within the tumor. In addition, these vascular networks
facilitate the physical recruitment of inflammatory cells
and the dissemination of metastatic cancer cells. As a
result, tumor vasculature has become an important
therapeutic target for molecular targeting agents [34].
In this study, we have used a genetically engineered
mouse model of PTEN-deficient prostate cancer to
demonstrate that targeting both dysplastic epithelial
cells and the stromal vascular network with sorafenib
suppresses tumor growth. Furthermore, we show
differences in sorafenib-induced patterns of molecular
response between CNPC and CRPC. We also provide
preclinical evidence for enhanced antitumor activity of
sorafenib when co-administered with everolimus in
CRPC.
The mouse model used in this study uses the human
PSA promoter to drive the conditional inactivation of
PTEN in the luminal cells of the adult prostate gland
[30]. In this manner, normal PTEN expression and func-
tion is maintained in other tissue. Inactivation of PTEN
results in the stage-specific development of prostate
cancer that recapitulates many of the features associated
with the human disease. Tumors in these mice arise
from normal tissues, but follow a multistage process of
disease progression. In essence, this provides an excellent
window of opportunity to evaluate the chemopreventive
effects of potential anticancer agents by evaluating differ-
ences in the rates of disease progression. In the present
study, pharmacological administration of sorafenib did
not alter the onset of cancer, nevertheless, it did suppress
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sorafenib correlated to the inhibition of cell proliferation
and the induction of apoptosis in epithelial cancer cells as
well as the reduction of MVD and reactive stroma in
non-epithelial tumor cells.
The therapeutic effects of sorafenib were also investi-
gated on established CNPC and CRPC. In both inter-
vention models, treatment with sorafenib significantly
inhibited cancer cell proliferation and MVD. However,
the administration of sorafenib yielded only modest,
statistically insignificant therapeutic responses. Interest-
ingly, it was only in the CNPC intervention model that
sorafenib induced apoptosis. It is also important to note
that sorafenib inhibited p-Erk1/2 in CNPC. Of note, the
treatment combination of sorafenib and everolimus
inhibited phosphorylation of GSK3β in CRPC mice
despite elevated levels of phosphorylated AKT. Never-
theless, phosphorylation of β-catenin increased suggest-
ing that the combination of so sorafenib and everolimus
might cooperate to suppress GSK3b activity in CRPC.
However, sorafenib elicited the upregulation of phos-
phorylated Erk1/2 and STAT3-pY727 in CRPC. The
activation of MAPK and STAT3 signal transduction
pathways has been associated with the abrogation of
apoptosis [35,36]. Typically, activation of STAT3 oc-
curs by cytokine mediated JAK phosphorylation of
tyrosine 705, however, a second phosphorylation site
exists at serine 727 and is phosphorylated through
MEK and its transient or constitutive activation in
cancer cells has been associated with survival [37,38].
This effect could very well explain why we did not
see the induction of apoptosis in CRPC mice treated
with sorafenib.
Previous reports have suggested that sorafenib could
inhibit prostate cancer cell survival by decreasing prolif-
eration and inducing apoptosis through the down-
regulating of AR. However, in our study, treatment with
sorafenib failed to downregulate AR expression in vivo.
In fact, treatment with sorafenib increased AR expres-
sion in CRPC. This effect could be attributed to the
increased levels of MAPK and STAT3 pathway activa-
tion resulting from sorafenib administration especially
since both MAPK and STAT3 signal pathways are asso-
ciated with the ligand independent activation of AR in
CRPC [39,40]. Still, the clinical efficacy of sorafenib
monotherapy for advance prostate cancer has been
limited despite favorable outcomes in other cancer types
such as kidney and liver [41,42]. We believe that the
findings from our study may shed some light for the
shortcomings of sorafenib monotherapy in treating
human CRPC.
Recent reports have shown that the treatment combin-
ation of sorafenib and mTOR inhibitors result in a greater
antitumor effect. [24,26-28]. Therefore, we hypothesizedthat by using the combination of sorafenib and everoli-
mus, we could target the tumor microenvironment as
well as direct cancer cell survival and compensatory
pathways that could possibly restore treatment responses
of CRPC. In both CNPC and CRPC intervention models,
combination therapy demonstrated a clear tendency of
improved tumor suppression. More importantly, the
treatment combination of sorafenib and everolimus
overcame therapeutic escape from single agent therapy
in CRPC.
Conclusions
In summary, we have utilized a genetically engineered
mouse model of prostate cancer to demonstrate differ-
ential effects of treatment with sorafenib in PTEN-
deficient CNCP and CRPC and provide mechanistic
insights into the molecular responses. Finally, we pro-
vide preclinical evidence for the development of targeted
treatment strategies based on the use of multikinase
inhibitors, such as sorafenib, in combination with
mTOR inhibitors for the treatment of advanced pros-
tate cancer.
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